Blockade of excess glutamate release from glioma cells with SAS prevents KCC2 downregulation in GBM cells (MacKenzie et al., 2016), implicating increased glutamate signaling in Cl− gradient dysregulation and aberrant GABAergic neurotransmission. The gene discussed is SLC12A5; the disease is glioblastoma.